Alcon: Needham reiterates Buy with PT raised to $107 from $90.
ByAinvest
Wednesday, Aug 20, 2025 6:31 am ET1min read
ALC--
Alcon is a leading vision care company with a diverse range of products, including contact lenses, lens care solutions, and surgical products. The company's latest acquisition of STAAR Surgical, a maker of implantable lenses, aims to strengthen its position in the refractive surgery market. This strategic move complements Alcon's existing laser vision correction portfolio, providing a more comprehensive range of surgical solutions for patients seeking alternatives to glasses or contact lenses.
The acquisition of STAAR Surgical, valued at approximately $1.5 billion, is expected to close within six to twelve months, subject to shareholder approval. The deal involves purchasing all outstanding shares of STAAR for $28 each in cash. This acquisition is aimed at leveraging STAAR's Collamer lenses, which are used to correct severe myopia and other vision problems without the need for corneal tissue removal.
Alcon's recent financial performance has been robust, with the company reporting quarterly revenue of $2.47 billion and a net profit of $350 million for the quarter ending March 31, 2025. These figures underscore Alcon's strong market position and growth potential in the eye care sector.
The continued 'Buy' rating from Needham reflects a positive outlook on Alcon's ability to capitalize on market opportunities and integrate STAAR's technology into its existing portfolio. Investors and financial professionals can expect Alcon to continue its expansion in the vision care market, driven by technological advancements and strategic acquisitions.
References:
[1] https://nz.finance.yahoo.com/quote/ALC.SW/
[2] https://techfundingnews.com/alcon-to-acquire-staar-surgical-in-1-5b-deal-for-vision-surgery-expansion/
[3] https://www.ainvest.com/news/kepler-capital-maintains-buy-rating-alcon-chf86-00-price-target-2508/
[4] https://www.ainvest.com/news/lensar-q2-earnings-revenue-10-merger-alcon-track-2025-close-2508/
STAA--
Alcon: Needham reiterates Buy with PT raised to $107 from $90.
Alcon Inc. (NYSE: ALC) has received a continued 'Buy' rating from Needham with a price target raised to $107 from $90. The analyst, David Saxon, reiterated the recommendation, aligning with the previous ratings. This indicates continued confidence in Alcon's vision care portfolio and strategic direction.Alcon is a leading vision care company with a diverse range of products, including contact lenses, lens care solutions, and surgical products. The company's latest acquisition of STAAR Surgical, a maker of implantable lenses, aims to strengthen its position in the refractive surgery market. This strategic move complements Alcon's existing laser vision correction portfolio, providing a more comprehensive range of surgical solutions for patients seeking alternatives to glasses or contact lenses.
The acquisition of STAAR Surgical, valued at approximately $1.5 billion, is expected to close within six to twelve months, subject to shareholder approval. The deal involves purchasing all outstanding shares of STAAR for $28 each in cash. This acquisition is aimed at leveraging STAAR's Collamer lenses, which are used to correct severe myopia and other vision problems without the need for corneal tissue removal.
Alcon's recent financial performance has been robust, with the company reporting quarterly revenue of $2.47 billion and a net profit of $350 million for the quarter ending March 31, 2025. These figures underscore Alcon's strong market position and growth potential in the eye care sector.
The continued 'Buy' rating from Needham reflects a positive outlook on Alcon's ability to capitalize on market opportunities and integrate STAAR's technology into its existing portfolio. Investors and financial professionals can expect Alcon to continue its expansion in the vision care market, driven by technological advancements and strategic acquisitions.
References:
[1] https://nz.finance.yahoo.com/quote/ALC.SW/
[2] https://techfundingnews.com/alcon-to-acquire-staar-surgical-in-1-5b-deal-for-vision-surgery-expansion/
[3] https://www.ainvest.com/news/kepler-capital-maintains-buy-rating-alcon-chf86-00-price-target-2508/
[4] https://www.ainvest.com/news/lensar-q2-earnings-revenue-10-merger-alcon-track-2025-close-2508/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet